FDA Approves New Treatments

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated

“This is an epic moment for the treatment of ATTR amyloidosis. We are very excited and hopeful for the expanding landscape of ATTR amyloidosis by the approval of tafamidis, the first drug approved for ATTR cardiomyopathy. Tafamidis will have a tremendous impact on patients with both hereditary and wildtype ATTR amyloidosis. Given the complexities of these diseases, increasing treatment options for patients is hugely important in disease management. Wildtype ATTR amyloidosis patients are being diagnosed now more than ever, and the approval of tafamidis represents a major success for this population.”

Vaishali Sanchorawala, MD

View all posts